AGMB

NASDAQ 已收盘

AgomAb Therapeutics NV

5.62 USD
▼-0.20-3.44%
盘后 5.60 -0.36%
2026-11-19
市值
$268.40M
市盈率
—
EPS
-4.51
股息率
—
52 周区间
5.50 – 17.82
成交量
320.73K
Beta
—
目标价
37.67
52W 低 5.5052W 高 17.82
价格走势

公司简介

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 cli...